Answers are grounded in this paper and cite their sources.
The addition of GRASPA®, especially at the 100 IU/kg dose level, is feasible in elderly patients without excessive toxicity and associated with durable asparagine depletion. (clinicaltrials.gov identifier NCT01523782).
No takes yet. Share an insight, caveat, or question.
Hunault et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: